◆ Profet
Sign up Log in

← All markets

Open 💼 Business & Finance General #14714
💬 Jump to comments

What will the FDA's decision be on Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences in 2026?

Call Yes 89Ᵽ Call No 11Ᵽ
89.00Ᵽ
seed price — no trades yet
Call Yes
87.00Ᵽ – 91.00Ᵽ
Call No
9.00Ᵽ – 13.00Ᵽ

📡 Kalshi: 89%
Two different numbers on purpose: Kalshi's is the outside reference, Profet's is what actually moves credits here.

87.00Ᵽ best bid · 91.00Ᵽ best ask

🟢 On Kalshi (at import): $2,806 volume
💰 20.00 contract(s) resting 👁 3 views ⚡ Instant liquidity via Quick Bet

Price history

This platform
Loading…

Log in to trade this market.

Order book

Loading…
Bids
10.00 87.00Ᵽ Log in
Call No 10.00 @ 13.00Ᵽ · if correct: +870.00Ᵽ · if wrong: −130.00Ᵽ
Asks
10.00 91.00Ᵽ Log in
Call Yes 10.00 @ 91.00Ᵽ · if correct: +90.00Ᵽ · if wrong: −910.00Ᵽ

How much do you disagree with this price?

Pick 1 (barely) to 5 (strongly) -- a pure sentiment vote, not a trade, not tied to credits.

Log in to add your own rating.

No one's rated this yet -- be the first.

Resolution

Source
Kalshi ✓ Verified source
Event cutoff
Rules
If the FDA's decision on Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences in 2026 is a full approval or an accelerated approval, the market resolves to Yes.

Comments

Log in to join the discussion.

No comments yet -- be the first to say something.